Phase 1 Study to Evaluate the Effect of the Investigational Anticancer Agent Sapanisertib on the QTc Interval in Patients With Advanced Solid Tumors

The aim of this phase 1 study was to determine the effects of sapanisertib on the heart rate–corrected QT (QTc) interval in patients with advanced solid tumors. Adult patients with advanced solid tumors were enrolled to receive a single sapanisertib 40‐mg dose. Blood samples for pharmacokinetic anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Chirag, Goel, Sanjay, Patel, Manish R., Rangachari, Lakshmi, Wilbur, Jayson D., Shou, Yaping, Venkatakrishnan, Karthik, Lockhart, A. Craig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586797/
https://www.ncbi.nlm.nih.gov/pubmed/32488989
http://dx.doi.org/10.1002/cpdd.808

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586797/
https://www.ncbi.nlm.nih.gov/pubmed/32488989
http://dx.doi.org/10.1002/cpdd.808

Ejemplares similares